A positive feedback loop of β-catenin/CCR2 axis promotes regorafenib resistance in colorectal cancer
Open Access
- 9 September 2019
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 10 (9) , 1-12
Abstract
Resistance to molecular targeted therapies is a significant challenge for advanced colorectal cancer (CRC). Understanding the underlying mechanisms and developing effective strategies against regorafenib resistance are highly desired in the clinic. Here, we screened the expression of chemokine receptors and identified CC chemokine receptor 2 (CCR2) as a top upregulated gene in regorafenib-resistant cells. CCR2 silencing alleviated drug tolerance in regorafenib-resistant cells, while overexpression of CCR2 enhanced CRC cells resistance to regorafenib. Moreover, CCR2-mediated regorafenib tolerance was demonstrated to be associated with AKT/GSK3β-regulated β-catenin stabilization. In turn, β-catenin modulation is sufficient to trigger the transcriptional activation of CCR2 expression. Clinically, high-CCR2 expression was correlated to shorter overall survival and disease-free survival of patients. A positive correlation between CCR2 and nuclear β-catenin expression was observed in a cohort of CRC tissues. Altogether, these findings suggest β-catenin and CCR2 are part of a positive-feedback loop, which sustains a high CCR2 expression level, conferring CRC cells resistance to regorafenib. Thus, targeting CCR2 may be a useful therapeutic strategy to alleviate regorafenib tolerance to increase the efficacy of CRC treatments.Keywords
Funding Information
- Natural Science Foundation of Shanghai Municipality (16ZR1421300)
- National Natural Science Foundation of China (81871933, 81871933, 81871933, 81871933, 81871933)
This publication has 37 references indexed in Scilit:
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- Recruitment of a Myeloid Cell Subset (CD11b/Gr1mid) via CCL2/CCR2 Promotes the Development of Colorectal Cancer Liver MetastasisHepatology, 2012
- CCL2/CCR2 Chemokine Signaling Coordinates Survival and Motility of Breast Cancer Cells through Smad3 Protein- and p42/44 Mitogen-activated Protein Kinase (MAPK)-dependent MechanismsJournal of Biological Chemistry, 2012
- Endothelial CCR2 Signaling Induced by Colon Carcinoma Cells Enables Extravasation via the JAK2-Stat5 and p38MAPK PathwayCancer Cell, 2012
- The Chemokine Superfamily RevisitedImmunity, 2012
- CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasisNature, 2011
- Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activityInternational Journal of Cancer, 2010
- Disrupted in Schizophrenia 1 Regulates Neuronal Progenitor Proliferation via Modulation of GSK3β/β-Catenin SignalingCell, 2009
- Oncogenic β-Catenin Signaling Networks in Colorectal CancerCell Cycle, 2005
- Wnt signalling in stem cells and cancerNature, 2005